Legal & General Group Plc Takes Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Legal & General Group Plc bought a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 57,243 shares of the company’s stock, valued at approximately $13,857,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new position in BeOne Medicines during the second quarter worth approximately $28,000. Farther Finance Advisors LLC purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at $39,000. Signaturefd LLC acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth $49,000. Parallel Advisors LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $59,000. Finally, FNY Investment Advisers LLC acquired a new position in BeOne Medicines in the second quarter valued at $121,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 27,803 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lai Wang sold 5,000 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 81,254 shares of company stock valued at $27,971,587. 6.62% of the stock is currently owned by insiders.

BeOne Medicines Price Performance

Shares of ONC stock opened at $340.61 on Friday. The firm has a fifty day simple moving average of $332.72 and a 200-day simple moving average of $299.13. The company has a market capitalization of $40.38 billion, a PE ratio of 667.86 and a beta of 0.31. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $170.99 and a twelve month high of $385.22. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03.

Analyst Upgrades and Downgrades

ONC has been the subject of a number of research analyst reports. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a research report on Monday, November 24th. Citigroup increased their price objective on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Finally, Guggenheim increased their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.79.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.